INMB

SEC source: 0001213900-24-035720 · ownership.xml · nonDerivative · entry 1

Juda Scott · CIK 0001767084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,603

F1 · shares: The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $8.445, for an aggregate purchase price of $249,997.34 pursuant to a securities purchase agreement dated April 19, 2024. The warrants are exercisable immediately upon issuance until the earlier of (i) the two year anniversary of the initial exercise date or (ii) thirty trading days following the reporting of the top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the "Termination Date") but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock, such officers, directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the Warrant.

SEC source: 0001213900-23-085758 · ownership.xml · nonDerivative · entry 1

Juda Scott · CIK 0001767084 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 37,000

F1 · ownership.nature: The Reporting Person's shares are held by Fossick Capital LP ("Fossick"), a limited partnership. The Reporting Person holds all voting and dispositive control over the Issuer's shares of common stock held by Fossick.

SEC source: 0001213900-23-057083 · ownership.xml · nonDerivative · entry 1

Schroeder Timothy j · CIK 0001767226 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See Footnote

Disclosed balance after: 82,187

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 22, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares of common stock were sold in multiple transactions ranging from $11.00 to $11.10, inclusive. The reporting person undertakes to provide to Inmune Bio Inc., any security holder of Inmune Bio Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the range set forth above.

F3 · ownership.nature: These shares of common stock are held by CTI Holdings, a company of which Mr. Schroeder is the majority shareholder. Mr. Schroeder has voting and investment control over these shares.

SEC source: 0001213900-23-021235 · primary_doc.xml · nonDerivative · entry 1

Moss David J · CIK 0001421930 · CFO, Treasurer & Secretary · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,250,151

F1 · shares: The Reporting Person purchased 2,500 shares of the Issuer's Common Stock in an open market transaction on March 17, 2023.

SEC source: 0001213900-23-013273 · ownership.xml · derivative · entry 1

ALLEN MARCIA · CIK 0001109769 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2033-02-15

F1 · derivative.exercise_date: 19,024 options granted pursuant to the 2021 Stock Incentive Plan, 7,313 options granted pursuant to the 2019 Stock Incentive Plan and 8,663 options granted pursuant to the 2017 Stock Incentive Plan. One third (1/3) of the Option will vest at the one-year anniversary of the grant date and the remaining unvested Option will become vested and exercisable 1/24th every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the grant date.

SEC source: 0001213900-23-013280 · ownership.xml · derivative · entry 1

Moss David J · CIK 0001421930 · CFO, Treasurer & Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,000

Underlying: Common Stock · 160,000 shares

Expires 2033-02-15

F1 · derivative.exercise_date: Granted pursuant to the 2021 Stock Incentive Plan. One third (1/3) of the Option will vest at the one-year anniversary of the grant date and the remaining unvested Option will become vested and exercisable 1/24th every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the grant date.

SEC source: 0001213900-23-013276 · ownership.xml · derivative · entry 1

Baracchini Edgardo Jr · CIK 0001291972 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2033-02-15

F1 · derivative.exercise_date: Granted pursuant to the 2021 Stock Incentive Plan. One third (1/3) of the Option will vest at the one-year anniversary of the grant date and the remaining unvested Option will become vested and exercisable 1/24th every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the grant date.

SEC source: 0001213900-23-013286 · ownership.xml · derivative · entry 1

Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,000

Underlying: Common Stock · 160,000 shares

Expires 2033-02-15

F1 · derivative.exercise_date: Granted pursuant to the 2021 Stock Incentive Plan. One third (1/3) of the Option will vest at the one-year anniversary of the grant date and the remaining unvested Option will become vested and exercisable 1/24th every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the grant date.

SEC source: 0001213900-23-013284 · ownership.xml · derivative · entry 1

Juda Scott · CIK 0001767084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2033-02-15

F1 · derivative.exercise_date: Granted pursuant to the 2021 Stock Incentive Plan. One third (1/3) of the Option will vest at the one-year anniversary of the grant date and the remaining unvested Option will become vested and exercisable 1/24th every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the grant date.

SEC source: 0001213900-23-013278 · ownership.xml · derivative · entry 1

Ganjei James Kelly · CIK 0001767300 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2033-02-15

F1 · derivative.exercise_date: Granted pursuant to the 2021 Stock Incentive Plan. One third (1/3) of the Option will vest at the one-year anniversary of the grant date and the remaining unvested Option will become vested and exercisable 1/24th every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the grant date.

SEC source: 0001213900-23-013282 · ownership.xml · derivative · entry 1

Schroeder Timothy j · CIK 0001767226 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2033-02-15

F1 · derivative.exercise_date: Granted pursuant to the 2021 Stock Incentive Plan. One third (1/3) of the Option will vest at the one-year anniversary of the grant date and the remaining unvested Option will become vested and exercisable 1/24th every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the grant date.

SEC source: 0001213900-22-030208 · ownership.xml · nonDerivative · entry 2

Moss David J · CIK 0001421930 · CFO, Treasurer & Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,247,651

F2 · price: Represents the average purchase price at a range of between $6.77 and $6.79 per share.

SEC source: 0001213900-22-030208 · ownership.xml · nonDerivative · entry 1

Moss David J · CIK 0001421930 · CFO, Treasurer & Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,244,651

F1 · price: Represents the average purchase price at a range of between $6.11 and $6.29 per share.

SEC source: 0001213900-22-030210 · ownership.xml · nonDerivative · entry 1

Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,520,698

F1 · price: Represents the average purchase price at a range of between $6.37 and $6.43 per share.

SEC source: 0001213900-22-014504 · ownership.xml · nonDerivative · entry 1

Moss David J · CIK 0001421930 · CFO, Treasurer & Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,236,951

F1 · price: The purchase price of the common stock being reported is the closing price per share immediately preceding the entering into of the binding agreement to issue the securities . These shares were purchased by the Reporting Person directly from Issuer.

SEC source: 0001213900-22-014509 · ownership.xml · nonDerivative · entry 1

Lowdell Mark William · CIK 0001767037 · Chief Scientific Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,496,383

F1 · price: The purchase price of the common stock being reported is the closing price per share immediately preceding the entering into of the binding agreement to issue the securities. These shares were purchased by the Reporting Person directly from Issuer.

SEC source: 0001213900-22-014507 · ownership.xml · nonDerivative · entry 1

Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,514,398

F1 · price: The purchase price of the common stock being reported is the closing price per share immediately preceding the entering into of the binding agreement to issue the securities . These shares were purchased by the Reporting Person directly from Issuer.

SEC source: 0001213900-22-014499 · ownership.xml · nonDerivative · entry 1

Ganjei James Kelly · CIK 0001767300 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,793

F1 · price: The purchase price of the common stock being reported is the closing price per share immediately preceding the entering into of the binding agreement to issue the securities. These shares were purchased by the Reporting Person directly from Issuer.

SEC source: 0001213900-22-014496 · ownership.xml · derivative · entry 1

ALLEN MARCIA · CIK 0001109769 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2032-03-20

F1 · derivative.exercise_date: Granted pursuant to the 2021 Stock Incentive Plan. One third (1/3) of the Option will vest at the one-year anniversary of the grant date and the remaining unvested Option will become vested and exercisable 1/24th every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the grant date.

SEC source: 0001213900-22-014504 · ownership.xml · derivative · entry 2

Moss David J · CIK 0001421930 · CFO, Treasurer & Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 130,000 shares

Expires 2032-03-20

F2 · derivative.exercise_date: Granted pursuant to the 2021 Stock Incentive Plan. One third (1/3) of the Option will vest at the one-year anniversary of the grant date and the remaining unvested Option will become vested and exercisable 1/24th every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the grant date.

SEC source: 0001213900-22-014497 · ownership.xml · derivative · entry 1

Baracchini Edgardo Jr · CIK 0001291972 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2032-03-20

F1 · derivative.exercise_date: Granted pursuant to the 2021 Stock Incentive Plan. One third (1/3) of the Option will vest at the one-year anniversary of the grant date and the remaining unvested Option will become vested and exercisable 1/24th every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the grant date.

SEC source: 0001213900-22-014509 · ownership.xml · derivative · entry 2

Lowdell Mark William · CIK 0001767037 · Chief Scientific Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,000

Underlying: Common Stock · 104,000 shares

Expires 2032-03-20

F2 · derivative.exercise_date: Granted pursuant to the 2021 Stock Incentive Plan. One third (1/3) of the Option will vest at the one-year anniversary of the grant date and the remaining unvested Option will become vested and exercisable 1/24th every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the grant date.

SEC source: 0001213900-22-014505 · ownership.xml · derivative · entry 1

Schroeder Timothy j · CIK 0001767226 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2032-03-20

F1 · derivative.exercise_date: Granted pursuant to the 2021 Stock Incentive Plan. One third (1/3) of the Option will vest at the one-year anniversary of the grant date and the remaining unvested Option will become vested and exercisable 1/24th every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the grant date.

SEC source: 0001213900-22-014507 · ownership.xml · derivative · entry 2

Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 130,000 shares

Expires 2032-03-20

F2 · derivative.exercise_date: Granted pursuant to the 2021 Stock Incentive Plan. One third (1/3) of the Option will vest at the one-year anniversary of the grant date and the remaining unvested Option will become vested and exercisable 1/24th every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the grant date.

SEC source: 0001213900-22-014500 · ownership.xml · derivative · entry 1

Juda Scott · CIK 0001767084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2032-03-20

F1 · derivative.exercise_date: Granted pursuant to the 2021 Stock Incentive Plan. One third (1/3) of the Option will vest at the one-year anniversary of the grant date and the remaining unvested Option will become vested and exercisable 1/24th every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the grant date.

SEC source: 0001213900-22-014499 · ownership.xml · derivative · entry 2

Ganjei James Kelly · CIK 0001767300 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2032-03-20

F2 · derivative.exercise_date: Granted pursuant to the 2021 Stock Incentive Plan. One third (1/3) of the Option will vest at the one-year anniversary of the grant date and the remaining unvested Option will become vested and exercisable 1/24th every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the grant date.

SEC source: 0001213900-21-060386 · ownership.xml · nonDerivative · entry 1

Juda Scott · CIK 0001767084 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 30,000

F1 · ownership.nature: The Reporting Person's shares are held by Fossick Capital LP ("Fossick"), a limited partnership. The Reporting Person holds all voting and dispositive control over the Issuer's shares of common stock held by Fossick.

SEC source: 0001213900-21-056738 · ownership.xml · nonDerivative · entry 1

Moss David J · CIK 0001421930 · CFO, Treasurer & Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,219,158

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001213900-21-056740 · ownership.xml · nonDerivative · entry 1

Lowdell Mark William · CIK 0001767037 · Chief Scientific Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,472,793

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001213900-21-056737 · ownership.xml · nonDerivative · entry 1

Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,490,674

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001213900-21-055418 · ownership.xml · nonDerivative · entry 1

Moss David J · CIK 0001421930 · CFO, Treasurer & Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,220,183

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001213900-21-055422 · ownership.xml · nonDerivative · entry 1

Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,494,300

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001213900-21-055421 · ownership.xml · nonDerivative · entry 1

Lowdell Mark William · CIK 0001767037 · Chief Scientific Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,473,494

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001213900-21-054640 · ownership.xml · nonDerivative · entry 2

Moss David J · CIK 0001421930 · CFO, Treasurer & Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,222,262

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001213900-21-054640 · ownership.xml · nonDerivative · entry 1

Moss David J · CIK 0001421930 · CFO, Treasurer & Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,222,275

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001213900-21-054644 · ownership.xml · nonDerivative · entry 1

Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,500,817

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001213900-21-054642 · ownership.xml · nonDerivative · entry 1

Lowdell Mark William · CIK 0001767037 · Chief Scientific Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,475,851

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001415889-21-004281 · form4-09082021_040906.xml · derivative · entry 2

Xencor Inc · CIK 0001326732 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 108,000 shares

Expires 2021-09-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares underlying this option vested in 36 equal monthly installments beginning on April 3, 2018.

SEC source: 0001415889-21-004281 · form4-09082021_040906.xml · nonDerivative · entry 1

Xencor Inc · CIK 0001326732 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,885,533

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001213900-21-045373 · ownership.xml · derivative · entry 2

Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 270,000

Underlying: Common Stock · 30,000 shares

Expires 2029-11-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: These options were exercised in a cash transaction by the Reporting Person under Rule 16(b)(3). The options were granted to the Reporting Person under the Company's 2019 Stock Incentive Plan.

SEC source: 0001213900-21-045373 · ownership.xml · nonDerivative · entry 1

Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,524,433

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: These options were exercised in a cash transaction by the Reporting Person under Rule 16(b)(3). The options were granted to the Reporting Person under the Company's 2019 Stock Incentive Plan.

SEC source: 0001213900-21-037560 · ownership.xml · derivative · entry 2

Moss David J · CIK 0001421930 · CFO, Treasurer & Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 275,000

Underlying: Common Stock · 25,000 shares

Expires 2029-11-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: These options were exercised in a cash transaction by the Reporting Person under Rule 16(b)(3). The options were granted to the Reporting Person under the Company's 2019 Stock Incentive Plan.

SEC source: 0001213900-21-037560 · ownership.xml · nonDerivative · entry 1

Moss David J · CIK 0001421930 · CFO, Treasurer & Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,223,417

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: These options were exercised in a cash transaction by the Reporting Person under Rule 16(b)(3). The options were granted to the Reporting Person under the Company's 2019 Stock Incentive Plan.

SEC source: 0001213900-21-036870 · ownership.xml · nonDerivative · entry 1

Schroeder Timothy j · CIK 0001767226 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 92,187

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 22, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $27.00 to $29.00, inclusive. The Reporting Person undertakes to provide to Inmune Bio, Inc., any security holder of Inmune Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the range set forth above.

F3 · ownership.nature: These shares of Common Stock are held by CTI Holdings, a company of which Mr. Schroeder is the majority shareholder. Mr. Schroeder has voting and investment control over these shares.

SEC source: 0001213900-21-036518 · ownership.xml · nonDerivative · entry 1

Schroeder Timothy j · CIK 0001767226 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 106,667

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 22, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $21.00 to $25.25, inclusive. The Reporting Person undertakes to provide to Inmune Bio, Inc., any security holder of Inmune Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the range set forth above.

F3 · ownership.nature: These shares of Common Stock are held by CTI Holdings, a company of which Mr. Schroeder is the majority shareholder. Mr. Schroeder has voting and investment control over these shares.

SEC source: 0001213900-21-036353 · ownership.xml · nonDerivative · entry 2

Moss David J · CIK 0001421930 · CFO, Treasurer & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,198,417

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $20.00 to $20.14, inclusive. The Reporting Person undertakes to provide to Inmune Bio, Inc., any security holder of Inmune Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the range set forth above.

SEC source: 0001213900-21-036355 · ownership.xml · nonDerivative · entry 2

Lowdell Mark William · CIK 0001767037 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,476,251

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $20.00 to $20.48, inclusive. The Reporting Person undertakes to provide to Inmune Bio, Inc., any security holder of Inmune Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the range set forth above.

SEC source: 0001213900-21-036352 · ownership.xml · nonDerivative · entry 2

Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,510,933

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $20.00 to $20.21, inclusive. The Reporting Person undertakes to provide to Inmune Bio, Inc., any security holder of Inmune Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the range set forth above.

SEC source: 0001213900-21-036353 · ownership.xml · nonDerivative · entry 1

Moss David J · CIK 0001421930 · CFO, Treasurer & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,214,719

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $20.00 to $20.03, inclusive. The Reporting Person undertakes to provide to Inmune Bio, Inc., any security holder of Inmune Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the range set forth above.

SEC source: 0001213900-21-036355 · ownership.xml · nonDerivative · entry 1

Lowdell Mark William · CIK 0001767037 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,500,401

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $20.00 to $20.04, inclusive. The Reporting Person undertakes to provide to Inmune Bio, Inc., any security holder of Inmune Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the range set forth above.